Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
17h
Mitchell Kapoor Recommends Buy for Neurogene Due to Strong NGN-401 Low-Dose Safety and Potential Upside
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Neurogene (NGNE – Research Report) and keeping the price target at ...
17h
Promising Outlook for Neurogene’s Low-Dose NGN-401 Program in Rett Syndrome
Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
US housing starts tumble
Suit over streaming issues
Toothpaste safety concern
TX board backs Bible lessons
Education secretary pick
Atmospheric river alert
MX gray wolf found dead
LA 'sanctuary city' ordinance
To spin off cable channels
US shuts Kyiv embassy
5 Brazilian officers arrested
Police officers shot in KY
CA wage measure rejected
Gold hits one-week high
Iran's uranium stockpile
Liam Payne’s funeral
Super Heavy Starship launch
Reuters hires Sally Buzbee
Loses at the Davis Cup
OKs landmine aid to UKR
Aid trucks looted in Gaza
To lead energy committee
'Bomb cyclone' hits US
Jets fire GM Joe Douglas
Targets CCP operatives in TX
To lead Medicare, Medicaid
AARO director testifies
Inter Miami coach resigns
Bitcoin breaches $94,000
Sells for record $121.2M
Related topics
Neurogene
Rett syndrome
Feedback